OBJECTIVE: The value of @entity3528 ( @entity3528 ) in @entity1 with recurrent @entity43 is controversial. The aim of this population-based study was to investigate the role of @entity3528 in the Netherlands. METHODS: Data of 408 @entity1 who underwent @entity3528 between 2000 and 2013 were retrospectively collected from 38 Dutch hospitals. Survival after complete and incomplete @entity3528 was estimated by Kaplan-Meier curves. Factors associated with @entity1349 ( @entity1349 ) were explored with Cox regression. RESULTS: Median @entity1349 after @entity3528 was 51 months (95% confidence interval [95% CI], 44.8-57.2). Complete @entity3528 was achieved in 295 (72.3%) @entity1 , with an @entity1349 of 57 months (95% CI, 49.0-65.0) compared with 28 months (95% CI, 20.8-35.2) in @entity1 with incomplete @entity3528 (log-rank test; P < 0.001). Nonserous histology (HR 0.65; 95% CI 0.45-0.95), a long progression free interval (hazard ratio [HR], 0.29; 95% CI, 0.07-1.18), a good performance status (HR, 0.68; 95% CI, 0.49-0.94), @entity3528 without preoperative chemotherapy (HR, 0.72; 95% CI, 0.51-1.01), and complete @entity3528 (HR, 0.46; 95% CI, 0.33-0.64) were prognostic factors for survival. CONCLUSIONS: This population-based retrospective study showed that there might be a role for @entity3528 in recurrent @entity43 especially when complete @entity3528 can be accomplished. However, before adopting @entity3528 as a standard treatment modality for recurrent @entity43 , results of 3 ongoing prospectively randomized trials are needed.

Surgery for Recurrent XXXX in the Netherlands: A Population-Based Cohort Study.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['epithelial ovarian cancer'] @entity3528 :: ('MESH:D006962', 'Disease') :: ['SCS', 'secondary cytoreductive surgery'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity43 :: (MESH:D010051,Disease) :: ['Epithelial Ovarian Cancer']
